← Leaderboards
Elena Molokanova
Neurano Bioscience
$3,992,983
Attributed
$4,243,138
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,243,138 · 5
By mechanism
R44$2,484,468 · 1
R43$1,425,130 · 3
R21$333,540 · 1
Top collaborators
- Igor R Efimov2 shared
- Luyao Lu2 shared
- Alex Savtchenko2 shared
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposMediatingEngineeringMemantineIn VivoNmda Receptor AntagonistBrainSide EffectSynaptic CleftFda ApprovedPropertyN-Methyl-D-Aspartate ReceptorsRouteGuidelinesSynapsesDesignDoseGlutamatesAffectBehavior TestBiological SciencesExtracellularNanotherapeuticLink
Grant awards (9)
Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for the treatment of opioid use disorder$810,889
R44 · FY2025 · DA · contact PI
Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for the treatment of opioid use disorder$837,882
R44 · FY2024 · DA · contact PI
Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for the treatment of opioid use disorder$835,697
R44 · FY2023 · DA · contact PI
Alzheimer's disease and novel nanotherapeutics exclusively targeting extrasynaptic NMDA receptors$56,626
R43 · FY2022 · AG · contact PI
Pre-Clinical Evaluation of a Rationally Designed Nanotherapeutic for Huntington's Disease$518,505
R43 · FY2021 · NS · contact PI
Alzheimer's disease and novel nanotherapeutics exclusively targeting extrasynaptic NMDA receptors$500,000
R43 · FY2021 · AG · contact PI
Graphene optoelectronic biointerfaces for enabling optical cardiac pacemaking$125,930
R21 · FY2021 · HL
Graphene optoelectronic biointerfaces for enabling optical cardiac pacemaking$207,610
R21 · FY2020 · HL
Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for treatment of opioid use disorders$349,999
R43 · FY2019 · DA · contact PI